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Brachytherapy (BT) has a long tradition in the 
treatment of malignancies and, in fact, radiation 
oncology did indeed start with brachytherapy be-
fore the advent of teletherapy equipment. However, 
with the technological advancements of external 
beam radiotherapy (EBRT), radiation oncologists 
lost many of the surgical procedural skills in BT 
over the last few decades. At present, there is a wor-
rying trend of rapid decline in the use of BT even 
for anatomical sites with proven efficacy [1, 2]. Un-
like EBRT, the literature on BT is limited even in 
the radical setting and, hence, unsurprisingly, the 
evidence of BT as a palliative treatment is scanty, 
with oesophageal and tracheal BT being an excep-
tion [3–5]. BT can safely deliver unparalleled large 
dose of radiation to the tumor while sparing the 
surrounding normal structure, thus improving the 
therapeutic ratio compared to EBRT modalities [6]. 
On top of the physical and radiobiological ben-
efit, BT is also more economical when compared 
to intensity modulated radiation therapy (IMRT) 
[7]. In this manuscript we are describing a case of 
metastatic squamous cell carcinoma of the right 
axilla from hypopharynx who had good palliation 
and quality of life from BT treatment to both the 
metastatic and primary site. 
AbstrAct
Brachytherapy (Bt) is an important local treatment of tumor and it can be applied to different anatomical sites either in a 
curative or palliative setting. Bt can deliver large dose of radiation to the tumor while sparing the surrounding normal tissue 
which translates into a better therapeutic ratio compared to external beam radiotherapy. However, the evidence for the use of 
brachytherapy in the palliative setting is lacking in the literature. In this case report, we describe the brachytherapy technique 
and outcome of a patient with squamous cell carcinoma of the hypopharynx who underwent palliative brachytherapy to the 
hypopharynx and metastatic tumor at the right axilla.
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case presentation
This interesting patient is an 86-year-old male, 
smoker of 40 pack years with severe smoking-relat-
ed lung disease. He quit smoking 20 years ago after 
being diagnosed with laryngeal cancer for which he 
underwent definitive EBRT and had been in disease 
remission since then. Despite the advanced age, 
he had been generally fit and independent till July 
2017 when he presented with a right axillary mass. 
He underwent surgery to remove the lesion at an-
other hospital and the exact nature of the mass, the 
diagnosis and clinical assessments that were made 
at that time is not known. Subsequently, there was 
a persistent non-healing ulcer at the excision site 
which was biopsy confirmed as poorly differenti-
ated squamous cell carcinoma one month later.
A staging positron emission tomographic 
(PET-CT) scan then showed an increased uptake 
in the right axilla (standardized uptake value, SUV 
8.6) and hypopharynx (SUV 7.6) with correspond-
ing contrast enhancing lesions in the CT-images. 
Fine needle aspiration biopsy (FNAB) of the hy-
popharyngeal lesion confirmed it as squamous cell 
carcinoma. He was re-assessed in the same hospital 
and was deemed unfit for surgery due to his age 
and extent of the local disease. Afterwards, he had 
a course of EBRT to 66 Gy in 33 daily fractions 
to the axilla, which was completed with interrup-
tions in the radiotherapy schedule due to intermit-
tent flaring of his smoking-induced lung disease. 
Despite initial 4 months of local control after the 
course of radiotherapy, the axillary lesion recurred 
and was rapidly increasing in size. He was then 
started on chemotherapy with oral Capecitabine. 
However, the axillary lesion progressed on chemo-
therapy and the oral Capecitabine was discontinued 
after 3 cycles.
When the patient first presented to our centre 
one year after the initial diagnosis of hypopharyn-
geal carcinoma metastatic to the axilla, he was un-
able to move the right shoulder due to severe pain 
with pain score of 9/10. He suffered from significant 
lymphoedema and total loss of both motor func-
tion and sensation in the right upper limb. There 
was a 12 × 7 cm foul smelling fungating lesion at 
the right axilla that bled spontaneously with move-
ment (Fig. 1). Patient`s general mobility was se-
verely limited due to pain and he was wheelchair 
bound. His Eastern Cooperative Oncology group 
(ECOG) performance status was 3. However, he 
was asymptomatic for the hypopharyngeal lesion 
and was tolerating orally well.
A repeat CT neck-thorax-abdomen-pelvis 
(NTAP) did not show any other metastatic disease; 
however, the local disease at the right axilla was 
extensive, involving the chest wall and right arm 
(Fig. 2A and 2B). The hypopharyngeal lesion was 
not eroding into the surrounding structures and 
there was no regional nodal involvement (staging 
according to AJCC 7th edition cT3N0M1).
After extensive discussion with the patient and 
his family members, taking into consideration his 
age, pre-existing severe smoking induced chronic 
lung disease and extent of the disease at the axilla, 
a mutual decision was made to have a good pallia-
tive procedure to improve the quality of life. Since 
the axillary lesion was unresectable and further 
high dose fractionated radiotherapy with EBRT 
could cause significant toxicity, palliative brachy-
therapy was suggested to which the patient and 
his family members agreed and consented. The 
risks of rib fracture at the site of treatment, chances 
of further worsening of lymphoedema, chronic 
non-healing ulcer at the axilla and surgical risks 
of brachial vessel rupture during the interstitial BT 
applicator insertion were explained in detail. Pa-
Figure 1. 12 × 7 cm foul smelling fungating lesion 
at the right axilla
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tient also understood that the nerve damage was 
probably permanent and may not improve with the 
expected axillary tumour shrinkage after BT.
The procedure was performed under general 
anaesthesia and doppler ultrasound guidance was 
used to avoid puncturing the brachial artery. The 
patient was positioned semi-supine with his body 
rotated 30 degrees to the left lateral. Tumour edges 
were palpated clinically and marked on the skin. 
Under ultrasound guidance the deep-seated tu-
mour areas and the course of the brachial artery 
were identified to be avoided. Introducers were in-
serted from the antero-medial to postero-lateral di-
rection by puncturing the skin and tumour through 
and through under real-time ultrasound guidance. 
6F flexible BT applicators with buttoned end On-
coSmart Catheter System (Elekta, Stockholm, Swe-
den) were introduced through the introducer and 
fixed at the postero-lateral side. In total, 15 BT ap-
plicators were used to cover the marked tumour 
area sufficiently (Fig. 3). Care was taken to ensure 
the spacing between applicators was within 3 cm 
to reduce hotspots. The procedure was uneventful 
with minimal bleeding. Puncture sites were cleaned 
and covered with povidone-soaked gauze.
The patient was CT-simulated with CT markers 
inserted into the placed BT applicators, acquiring 
2mm contrasted axial slices in the region of interest. 
Tumour was identified and contoured in each slice 
as gross tumor volume (GTV) and a 5 mm safety 
margin was expanded automatically as the planning 
target volume (PTV). Care was taken to avoid the 
shoulder joint in the PTV where possible without 
compromising GTV coverage. A total dose of 54 Gy 
to cover the PTV was prescribed. 
Brachytherapy dose planning to the target was 
performed using the Oncentra Masterplan V 4.5.3 
brachytherapy treatment planning system (TPS) 
(Nucletron BV, Veenendaal, The Netherlands) 
which had an inverse planning capability. The target 
coverage was manipulated by adjusting the dwell 
time and dwell position of the Ir-192 source with an 
initial activity of 10 MCi. The 15 ProGuide plastic 
applicators of 240 mm in length (Elekta, Stock-
holm, Sweden) were reconstructed in the brachy-
therapy TPS. 500 normalisation points were created 
at the PTV surface. After achieving a good dose 
distribution (D90 of PTV receiving 7.23 Gy per 
fraction) with further manual graphical optimisa-
tion of the isodoses, the final plan was exported to 
the high dose rate (HDR) Nucletron remote after 
loader system (Fig. 4). The patient was treated with 
one fraction of 6 Gy daily for 9 consecutive days. 
Applicators were removed after completing the 9 
days of treatment which was uneventful. 
One week later, patient’s pain score had gone 
down to 3/10 from the pre-treatment score of 9/10. 
The axillary fungating mass had flattened and there 
was no more spontaneous bleeding (Fig. 5). At 
1-month post treatment, the fungating lesion had 
completely resolved leaving a 5 × 4 cm of sloughy 
region. The patient was pain-free in the axilla and 
Figure 2Ab. axial slice of ct showing extensive right axilla 
lesion involving the chest wall and right arm
a
B
Figure 3. 15 applicators were used to cover the marked 
tumour area sufficiently
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his ECOG performance status improved from 
ECOG-3 initially to ECOG-2.
Unfortunately, 2 months after brachytherapy, 
a repeat CT-NTAP showed liver and lung me-
tastases, though the axillary lesion was much re-
duced in size in all dimensions with minimal con-
trast enhancing areas within the residual tumour. 
As the patient was unfit for any systemic therapy 
and asymptomatic at both the primary and meta-
static sites, we opted for no active oncological 
intervention and he was referred to the pallia-
tive care team. Clinically, the axillary tumour site 
showed telangiactesia at the periphery and slough 
covered cavity with no significant pain or active 
bleeding (Fig. 6).
Four months after the brachytherapy to the ax-
illa, the patient presented to us again, this time 
with dysphagia tolerating liquid diet only. Laryn-
go-oesophagoscope showed near complete obstruc-
tion of the hypopharyngeal region by the tumour. 
Interestingly, the right axillary region did not show 
any clinical sign of local recurrence (Fig. 7A and B). 
The patient was unable to lie flat due to the pre-ex-
isting lung disease which made palliative EBRT to 
the neck region a difficult task. He was not keen 
on feeding percutaneous endoscopic gastrostomy 
(PEG) tube insertion. As such, we proceeded with 
palliative brachytherapy to the hypopharyx after 
informed consent from the patient.
Nucleotron (Veenendaal, The Netherlands) intra 
luminal applicator was inserted up to the lower oe-
sophagus after a mild dilatation of the hypopharynx 
and upper oesophagus by the surgeon. Patient was 
CT-simulated in a semi-supine position (30-degree 
elevation) with intravenous contrast and CT-mark-
er in situ. The tumour was marked as GTV in each 
of the 2 mm CT slices. A dose of 12 Gy in a single 
fraction was prescribed to cover the GTV using the 
Oncentra Masterplan V 4.5.3 brachytherapy TPS. 
Then, the isodoses were normalized and adjusted 
Figure 4. Final isodose plan after optimization
Figure 5. one-week post treatment, the axillary fungating 




Figure 6. the axillary tumour site showed telangiactesia at 
the periphery and slough covered cavity with no significant 
pain or active bleeding
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graphically to have the 100% isodose covering 1 
cm depth laterally from the centre of the applica-
tor (Fig. 7A). Due to the geographical position of 
the tumor, 0.5 cm safety margin superiorly and 1.5 
cm inferiorly of the GTV (Fig. 7B) was assigned. 
The dwell time and position of the Ir-192 source 
was assigned automatically by the brachytherapy 
inverse planning TPS. The patient was treated with 
Nucleotron (Veenendaal, The Netherlands) HDR 
after loader brachytherapy system and the intra-
luminal applicator was removed immediately after 
the procedure.
Two weeks after the brachytherapy to hypophar-
ynx, the patient was tolerating semi-solid diet and 
his dysphagia score had improved from grade 4 
to 2. There were symptoms of grade 1 (Common 
Terminology Criteria for Adverse Events, CTC-AE 
4.0) pharyngitis and oesophagitis. His axillary re-
gion was pain-free with no active bleeding. There 
were no clinical signs of recurrence. The upper limb 
lymphoedema had also improved. Unfortunately, 
patient’s general condition deteriorated thereafter, 
most likely due to the progression of the visceral 
disease and two weeks later he succumbed to his 
disease.
Discussion
HDR brachytherapy (HDRBT) is an important 
radiation therapy modality that can be used in the 
surface, intracavitary, intraluminal or interstitial 
application. The main advantage of HDR brachy-
therapy is that it allows high dose of radiation to 
be delivered to a pre-defined target volume while 
achieving a good sparing the adjacent normal tis-
sue [3]. Despite being the first radiation modality 
to be used clinically, it’s usage has dropped in recent 
times compared to historically available data [1, 2]. 
Many radiation oncologists consider brachyther-
apy as an invasive procedure as it requires certain 
surgical skills that come with proper training. The 
emphasis on BT is also lacking in most radiation 
oncology residency programs, except for gynaeco-
logical and prostate cancers [8]. Furthermore, with 
the advent of technology, such as the highly com-
plex modern linear accelerator (LINAC), which are 
readily available in many radiotherapy centres, less 
emphasis was given to BT. This phenomenon con-
tinues despite most radiation oncologists agreeing 
on the superiority of BT dose conformality whilst 
sparing the normal tissues compared to other avail-
able EBRT technology [6].
The goal of palliative radiotherapy is to alleviate 
symptoms in the shortest amount of time, main-
tain an optimal function and quality-of-life while 
minimizing toxicity and patient inconvenience [9]. 
A wide range of symptoms from advanced cancer 
is treated with palliative radiotherapy such as pain, 
bleeding, dysphagia, dyspnoea and to relieve neuro-
logical symptoms. Clinical trials have demonstrated 
that hypofractionated treatment provides equiva-
lent symptomatic benefit to longer courses, with 
limited toxicity [3, 10]. Though these hypofraction-
ated palliative radiotherapy can be delivered via 
EBRT or BT, evidence for palliative BT is still lack-
ing in the literature as compared to palliative EBRT.
Studies have revealed improved local control 
with dose escalation, however the tolerance of 
the normal surrounding structures is a major is-
sue in EBRT [11]. Due to the physical nature 
of radiation from the Ir-192 radioactive source 
average radiation dose received by the tumor is 
much higher than the prescribed dose at the pe-
Figure 7A. the isodoses were normalized and adjusted 
graphically as to have the 100% isodose covering 1 cm 
depth laterally from the from the centre of the applicator; 
b. Due to the geographical position of the tumor, 0.5 cm 
safety margin superiorly and 1.5 cm inferiorly of the gross 
tumor volume (GtV) was assigned
a
B
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riphery of the TV [12]. Another distinct feature 
of HDRBT is that the radiation doses within the 
vicinity of an implant are higher than the maxi-
mum dose levels generally accepted in EBRT pro-
tocols, and yet they are well tolerated because of 
the dose-volume relationship (small volumes can 
tolerate very high doses of radiation). These phys-
ical and radiobiological properties of BT gives it 
a great unexplored potential for tumors in many 
organ sites, e.g. overcoming radio resistance and 
focused radiation in critical organs such as the 
liver and in re-irradiation. Thus, by enhancing the 
local tumour control, BT, when used alone or in 
addition to EBRT, has a great potential in achiev-
ing the goals of palliation.
The optimal radiation dose and fractionation 
for palliative BT is unknown [13]. There is also 
little evidence in the literature on the optimal 
radiation doses for BT with regard to tumour his-
tology, unlike in the setting of fractionated EBRT. 
Our patient had initially received a total of 66 Gy 
in 2Gy per fraction of EBRT to the right axillary 
mass. The fact that the tumour in the right axilla 
recurred within 4 months of EBRT points towards 
a more radioresistant clones. The good tumour 
response with BT in this patient can be attributed 
to the large dose per fraction that was used. Expe-
rience with Stereotactic Radiation Therapy (SRT) 
showed that a larger fractional dose may have 
a strong role in overcoming radio-resistance [14]. 
In this patient, the expected survival was less than 
a year and aim of the treatment was to achieve 
a good local control and improve the quality of 
life with minimal emphasis on the long-term side 
effects associated with the large fractional dose 
delivered. Furthermore, the patient already had 
a complete neurological deficit of the right up-
per limb. The immediate improvement in pain 
symptoms and bleeding as early as 1 week after 
BT and complete tumor resolution in the right 
axilla at 4 months confirms the efficacy of this 
short course of HDRBTThe palliative treatment 
options for the hypopharyngeal tumour at that 
point was PEG-tube for feeding, which the patient 
refused, palliative EBRT and BT. Stenting was 
not feasible given the location of the tumour. As 
the tumour was quite circumferential around the 
upper oesophagus and compounded by the fact 
that the patient can’t lie flat for EBRT, intralumi-
nal oesophageal BT was deemed the best option 
for him to improve dysphagia. In a 2004 Lancet 
paper, Homs et al. showed that single dose of 
brachytherapy (12 Gy) caused a better improve-
ment in long term dysphagia scores than a metal 
stent placement. Quality-of-life scores were also 
in favour of brachytherapy as compared to stent 
placement [3]. Similar findings were also shown 
by Berqguist et al. in a study that randomised 65 
patients with advanced cancer of the oesopha-
gus to either an expandable stent placement or 
HDR endoluminal brachytherapy to a total dose 
of 21 Gy divided into 3 equal fractions, given over 
2–4 weeks [12]. Palliative brachytherapy with or 
without stent placement should therefore always 
be considered in all patients with a life expec-
tancy exceeding 3 months with stent insertion 
as the sole treatment reserved for patients with 
an extremely short life expectancy where the im-
mediacy of symptomatic relief offered by this pro-
cedure clearly dominates. Our patient had a good 
palliation and was able to tolerate orally after the 
single dose of 12 Gy palliative intraluminal BT to 
the hypopharynx and upper oesophagus for the 
final 1 month of his life.
Despite the advances in systemic antineoplastic 
therapies, such as newer generation cytotoxic che-
motherapy, molecular targeted therapy and immu-
notherapy, failure to control the tumour at its pri-
mary or metastatic site/s remains the predominant 
source of morbidity and often mortality in many 
cancer patients. This patient was not fit for aggres-
sive systemic treatments in view of his age, co-mor-
bidities and performance status. As his symptoms 
were localized to the tumor at the hypopharynx and 
right axilla, any attempt at an aggressive systemic 
therapy would have been of doubtful benefit. A very 
effective, simple and minimally invasive procedure 
which BT is, gave him a good quality of life for 6 
months after the initial brachytherapy to the axilla.
In experienced hands, BT offers an elegant and 
minimally invasive way to safely deliver relatively 
large dose of radiation to the tumour while spar-
ing the adjacent tissue. Good tumour response, 
as seen in this patient, is not uncommon for BT. 
More patients will benefit if the use of BT is fur-
ther expanded and not limited to just a few organ 
sites in the palliative setting. Brachytherapy is an 
important trade and weapon owned by radiation 
oncologists that needs resurrection for the benefit 
of cancer patients.
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conclusions
Brachytherapy is a well-tolerated treatment op-
tion in selected patients with advanced cancer. It 
is a safe and effective treatment modality in expe-
rienced hands for palliation of advanced cancer, 
yielding a good local control with acceptable treat-
ment-related side effects. In this case, the patient 
expectedly had a relatively good quality of life in 
terms of pain control, bleeding and dysphagia.
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